Arbidol Maximum 200 mg 20 capsules

Prevention and treatment in adults and children aged 12 and older: influenza A and B, other acute respiratory viral infections (ARVI).
Comprehensive therapy for recurrent herpes infections.
Prevention of postoperative infectious complications.
Comprehensive therapy for acute intestinal infections of rotavirus etiology in children over 12 years old.

Orally, before meals.
Single dose for adults and children over 12 years old - 200 mg (1 capsule).
Indications Dosage regimen
For adults and children over 12 years old:
Non-specific prophylaxis during the influenza epidemic and other acute respiratory viral infections (ARVI) at a single dose 2 times a week for 3 weeks.
Non-specific prophylaxis upon direct contact with patients with influenza and other ARVI at a single dose once a day for 10-14 days.
Treatment of influenza and other ARVI at a single dose 4 times a day (every 6 hours) for 5 days.
Comprehensive therapy for recurrent herpes infection at a single dose 4 times a day (every 6 hours) for 5-7 days, then at a single dose 2 times a week for 4 weeks.
Prophylaxis of postoperative infectious complications at a single dose 2 days before surgery, then on days 2 and 5 after surgery.
For children from 12 years:
Comprehensive therapy for acute intestinal infections of rotavirus etiology at a single dose 4 times a day (every 6 hours) for 5 days.
The medication should be started at the onset of the first symptoms of influenza and other ARVI, preferably no later than 3 days from the onset of the illness.
If, after taking Arbidol® Maximum for three days in the treatment of influenza and other ARVI, the severity of symptoms persists, including high fever (38 °C and above), it is necessary to consult a doctor to assess the appropriateness of continuing the medication.
Use the medication only according to the indications, method of administration, and dosages specified in the instructions.
In the treatment of influenza and ARVI, concomitant symptomatic therapy may be possible, including the use of antipyretic agents, mucolytics, and local vasoconstrictors.

Per capsule:
active ingredient: umifenovir hydrochloride monohydrate - 207.0 mg (calculated as umifenovir hydrochloride) - 200.0 mg.
excipients: potato starch - 45.67 mg, microcrystalline cellulose 200 - 11.20 mg, colloidal silicon dioxide - 2.80 mg, povidone K25 (Kollidon) - 7.73 mg, calcium stearate - 2.80 mg, sodium croscarmellose - 2.80 mg, hard gelatin capsules No. 0:
capsule shell composition (body and cap): titanium dioxide (E 171) - 1.92 mg, gelatin - 94.08 mg.

Hard gelatin capsules No. 0, white in color. The contents of the capsule are a mixture containing granules and powder ranging from white or white with a yellowish or greenish-yellow tint to light yellow or light yellow with a greenish tint.

Increased sensitivity to umifenovir or any component of the drug; age under 12 years.
First trimester of pregnancy.
Period of breastfeeding.

With caution:
Second and third trimesters of pregnancy.
Pregnancy and lactation:
Animal studies have not revealed harmful effects on the course of pregnancy, embryonic and fetal development, labor, and postnatal development.
The use of Arbidol® Maximum in the first trimester of pregnancy is contraindicated.
In the second and third trimesters of pregnancy, Arbidol® Maximum may be used only for the treatment and prevention of influenza and only if the expected benefit to the mother outweighs the potential risk to the fetus. The benefit/risk ratio is determined by the attending physician.
It is unknown whether Arbidol® Maximum penetrates into breast milk in women during lactation. If Arbidol® Maximum is necessary, breastfeeding should be discontinued.

It is necessary to follow the recommended dosage regimen and duration of the medication as stated in the instructions. In case of a missed dose, it should be taken as soon as possible, and the course of the medication should be continued according to the established regimen.
If symptoms of the disease, including high fever (38 °C and above), persist for three days after using Arbidol® Maximum for the treatment of influenza and other acute respiratory viral infections (ARVI), it is necessary to consult a doctor to assess the appropriateness of continuing the medication.

Effect on the ability to drive vehicles and operate machinery:
It does not exhibit central neurotropic activity and can be used in medical practice by individuals in various professions, including those requiring increased attention and coordination of movements (drivers, operators, etc.).

The drug Arbidol® Maximum is classified as a low-toxicity medication and is usually well tolerated.
Side effects occur rarely, typically being mild or moderate in severity and transient in nature.
The frequency of adverse drug reactions is defined according to the WHO classification: very common (frequency greater than 1/10), common (frequency of at least 1/100 but less than 1/10), uncommon (frequency of at least 1/1000 but less than 1/100), rare (frequency of at least 1/10000 but less than 1/1000), very rare (frequency less than 1/10000), frequency unknown (cannot be established from available data).
Immune system disorders:
rare - allergic reactions.

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not mentioned in the instructions, inform your doctor.

Not noted.

No negative effects have been noted when prescribed with other medications.

Special clinical studies dedicated to the interaction of Arbidol® Maximum with other medications have not been conducted.

Information regarding the presence of undesirable interactions with antipyretics, mucolytics, and local vasoconstrictors in clinical research conditions has not been identified.

Antiviral agent. Specifically suppresses in vitro influenza A and B viruses (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1) pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (ARVI) (coronavirus associated with severe acute respiratory syndrome (SARS), rhinovirus, adenovirus, respiratory syncytial virus, and parainfluenza virus).
In in vitro studies, it specifically suppresses the SARS-CoV-2 virus, which causes the new coronavirus infection (COVID-19). The EC50 (half-maximal effective concentration) in Vero E6 cells is 4.11 μmol, corresponding to 2.11 μg/ml. The clinical significance of this requires further study.
By its antiviral mechanism, it belongs to fusion inhibitors, interacts with the virus hemagglutinin, and prevents the fusion of the viral lipid envelope with cell membranes. It has a moderate immunomodulatory effect, increasing the body's resistance to viral infections. It possesses interferon-inducing activity - in a study on mice, interferon induction was noted as early as 16 hours, and high levels of interferons were maintained in the blood for up to 48 hours after administration. It stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helper cells (CD4) without affecting the level of T-suppressor cells (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages, and increases the number of natural killers (NK cells).
Therapeutic efficacy in viral infections is manifested in the reduction of the duration and severity of the disease and its main symptoms, as well as in the decrease in the frequency of complications associated with viral infection and exacerbations of chronic bacterial diseases.

In the treatment of influenza or ARVI in adult patients, clinical studies have shown that the effect of the drug in adult patients is most pronounced in the acute phase of the disease, manifested by a reduction in the duration of symptom resolution, a decrease in the severity of disease manifestations, and a shortening of the virus elimination period.
Therapy with the drug leads to a higher frequency of symptom relief by the third day of therapy compared to placebo - 60 hours after the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza exceeds the corresponding figure in the placebo group by more than 5 times.
A significant effect of the drug on the rate of influenza virus elimination has been established, which, in particular, was manifested by a decrease in the frequency of RNA virus detection on the fourth day.
It is classified as a low-toxicity drug (LD50 > 4 g/kg). It does not exert any negative effects on the human body when taken orally at recommended doses.

Rapidly absorbed and distributed throughout organs and tissues. Maximum plasma concentration after administration of a 50 mg dose is reached in 1.2 hours; for a 100 mg dose, it is reached in 1.5 hours. Metabolized in the liver. The average half-life is 17-21 hours. Approximately 40% is excreted unchanged, primarily in bile (38.9%) and in a small amount by the kidneys (0.12%). Within the first 24 hours, 90% of the administered dose is eliminated.